Findings in Melanoma Reported from UPMC Hillman Cancer Center (Neoadjuvant Pembrolizumab and High-dose Ifn Alpha-2b In Resectable Regionally Advanced Melanoma)

Source :: Immunotherapy Weekly. September 1, 2021, 365
Publication Year :: 2021
Abstract: 2021 SEP 1 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators publish new report on Oncology - Melanoma. According to news reporting originating in Pittsburgh, [...]

Subjects :: Merck & Company Inc. -- Reports
Care and treatment
Research
Reports
Dosage and administration
Cancer -- Care and treatment
Immunotherapy -- Reports -- Research
Pembrolizumab -- Dosage and administration -- Research
Pharmaceutical industry -- Reports -- Research
Melanoma -- Research -- Care and treatment

Tools